Thetis Pharmaceuticals Preclinical Data Shows Efficacy of TP-317 in Ulcerative Colitis and Crohn’s Disease Models with Unique Mucosal Healing Mechanism of Action

TP-317 represents a novel approach to treating inflammatory bowel disease (IBD) based on activating intrinsic resolution and repair pathways without compromising immune function BRANFORD, CT – (May 18, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company with platform technology developing a new class of Resolvin-based therapies for gastrointestinal inflammatory diseases, today announced preclinical data […]

Dr. Ronald Lennox Joins the Board of Directors of Thetis Pharmaceuticals as it Transitions into a Clinical Stage Biotechnology Company

BRANFORD, CT – (May 6, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company focused on novel gastrointestinal therapies that promote mucosal healing, announced today that Ron Lennox, D.Phil., has joined its Board of Directors. Dr. Lennox, a prolific biotechnology entrepreneur and investor over the last 30 years, will work with Thetis senior management as […]

Charles N. Serhan, PhD, DSc, Leading Expert in Inflammation Resolution Pharmacology, Joins Thetis Pharmaceuticals Scientific Advisory Board

Professor Serhan to guide advancement of resolvin-based therapies into clinical investigation for treatment of inflammatory diseases BRANFORD, CT – (February 19, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing Resolvin-based therapies to treat inflammatory diseases, announced today that Professor Charles N. Serhan has joined its Scientific Advisory Board. Dr. Serhan’s pioneering studies on […]

Thetis Awarded Key Composition of Matter Patents on Resolvin-based Agents

Provides a platform for the development of Resolvin therapies in inflammatory bowel disease and other inflammation disorders BRANFORD, CT – (January 22, 2019) – Thetis Pharmaceuticals, a privately-held biopharmaceutical company developing novel small molecule therapies based on a class of potent pro-resolving lipid mediators known as Resolvins, announced today that the U.S. Patent and Trademark […]

Thetis Selected to Present TP-317 Program at IBD Innovate Conference

Novel Resolvin-based drug candidate offers potential first-in-class, oral, small molecule therapy for IBD BRANFORD, CT – (November 13, 2018) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing novel Resolvin-based therapies to treat inflammatory diseases, was selected by the Crohn’s & Colitis Foundation to present on TP-317, its lead drug candidate for inflammatory bowel disease […]